Eli Lilly and Company
LLY · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $45,042,700 | $34,124,100 | $28,541,400 | $28,318,400 |
| % Growth | 32% | 19.6% | 0.8% | – |
| Cost of Goods Sold | $8,418,300 | $7,082,200 | $6,629,800 | $7,312,800 |
| Gross Profit | $36,624,400 | $27,041,900 | $21,911,600 | $21,005,600 |
| % Margin | 81.3% | 79.2% | 76.8% | 74.2% |
| R&D Expenses | $10,990,600 | $9,313,400 | $7,190,800 | $6,930,700 |
| G&A Expenses | $8,132,100 | $6,941,200 | $6,067,500 | $6,141,900 |
| SG&A Expenses | $8,132,100 | $6,941,200 | $6,067,500 | $6,141,900 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $19,122,700 | $16,254,600 | $13,258,300 | $13,072,600 |
| Operating Income | $17,501,700 | $10,787,300 | $8,653,300 | $7,933,000 |
| % Margin | 38.9% | 31.6% | 30.3% | 28% |
| Other Income/Exp. Net | -$4,821,300 | -$4,232,700 | -$1,846,900 | -$1,777,500 |
| Pre-Tax Income | $12,680,400 | $6,554,600 | $6,806,400 | $6,155,500 |
| Tax Expense | $2,090,400 | $1,314,200 | $561,600 | $573,800 |
| Net Income | $10,590,000 | $5,240,400 | $6,244,800 | $5,581,700 |
| % Margin | 23.5% | 15.4% | 21.9% | 19.7% |
| EPS | 11.76 | 5.83 | 6.57 | 5.85 |
| % Growth | 101.7% | -11.3% | 12.3% | – |
| EPS Diluted | 11.71 | 5.8 | 6.57 | 5.85 |
| Weighted Avg Shares Out | 900,605 | 899,379 | 950,182 | 953,653 |
| Weighted Avg Shares Out Dil | 904,059 | 903,284 | 950,182 | 953,653 |
| Supplemental Information | – | – | – | – |
| Interest Income | $175,200 | $173,600 | $62,800 | $25,400 |
| Interest Expense | $780,600 | $485,900 | $331,600 | $339,800 |
| Depreciation & Amortization | $1,766,600 | $1,527,300 | $1,522,500 | $1,547,600 |
| EBITDA | $15,227,600 | $8,567,800 | $8,660,500 | $8,042,900 |
| % Margin | 33.8% | 25.1% | 30.3% | 28.4% |